Pancreatic adenocarcinoma (PDAC) is one of the most deadly forms of cancer, in part due to the majority of diagnoses being late-stage; the five-year surviv...
Catalent does not endorse TRC’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to this unsolic...
Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced positive results today from the pedia...
The EVAQ Trial enrolled 121 patients at 17 centers globally. Data from the study will be used as part of an application to the U.S. Food and Drug Administr...
Akorn Operating Company LLC has filed Chapter 7 bankruptcy on February 23, 2023. In connection with that filing, the company has ceased and shutdow...
With research and development being a time-consuming industry, there is a constant need for time-saving digital solutions and tools. Nowadays, most laborat...
NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received a ...
Mrs. Jaeger has been an instrumental part of DAS Health since joining the company as Chief Operating Officer in 2021 and subsequently being promoted to Pre...
The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, randomized, masked, controlled IDE clinical study...
PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Austr...
Rakovina Therapeutics also announced that it will issue approximately thirty (30) unsecured $50,000 convertible debenture units to a select group of i...
Aquavit will begin its Phase II/Phase III trials for DTX-023 (aqubotulinumtoxinA) and DTX-024 (aqubotulinumtoxinA with intradermal microinjector) under the...
Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Res...
Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need T...
© 2024 Biopharma Boardroom. All Rights Reserved.
